Via practica 12/2009
Overview of results in selected pharmacoeconomic study of irbesartan
Cardiovascular diseases and diabetic kidney disease belong among leading cause of death in the developed world. Patients with diabetes type 2 have approximately a 50 percent risk of having kidney disease, which is associated with continual progression to kidney failure. If we look at the analyses conducted in the U.S. or Europe, they show that early treatment of eligible patients with irbesartan brings economic savings and increased life expectancy for patients.
Keywords: irbesartan, diabetes, hypertension, pharmacoeconomy.
